Cencora Inc. (COR)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x for...

Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and...

Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.

Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

Cencora (COR) came out with quarterly earnings of $4 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.34 per share a year ago.

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On...